Nat. Biotechnol. 26, 957–959 (2008); published online 7 November 2008; corrected after print 5 December 2008
In the version of this article initially published, on p. 958, right-hand column, line 2, it was incorrectly stated that Rituxan is used for treating multiple sclerosis: “Rituxan (rituximab), a B cell–depleting biologic for treating rheumatoid arthritis and multiple sclerosis, has shifted the focus towards B cells.” The sentence should have read, “Rituxan (rituximab), a B cell–depleting biologic for treating rheumatoid arthritis and non-Hodgkin's lymphoma, has shifted the focus towards B cells.” The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt0908-957
Rights and permissions
About this article
Cite this article
Melton, L., Coombs, A. Erratum: Actemra poised to launch IL-6 inhibitors. Nat Biotechnol 26, 1383 (2008). https://doi.org/10.1038/nbt1208-1383c
Issue Date:
DOI: https://doi.org/10.1038/nbt1208-1383c